June 3, 2020 / 1:53 PM / a month ago

BRIEF-Karolinska Development: Aprea Therapeutics Completes Enrollment In Phase 3 Study Of Eprenetapopt

June 3 (Reuters) - Karolinska Development AB:

* KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY APREA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF EPRENETAPOPT

* TOPLINE RESULTS ARE EXPECTED BY YEAR-END 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below